Immediate Impact of Switching from Dipeptidyl Peptidase  4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study
ConclusionSwitching from a DPP4 inhibitor to low-dose (0.3  mg) liraglutide once daily significantly reduced the blood glucose levels and excursions of the blood glucose levels even from the very day after the treatment switch, with no serious adverse events. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 18, 2024 Category: Endocrinology Source Type: research

Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups
ConclusionsIn this post hoc analysis, tirzepatide was associated with reduced blood glucose and body weight in a predominantly Chinese population with T2D across different subgroups, consistent with previous reports for tirzepatide.Clinical Trial RegistrationNCT04093752. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 18, 2024 Category: Endocrinology Source Type: research

Evaluating the Safety and Efficacy of Sodium-Glucose Co-transporter  2 Inhibitors in Subjects with Prediabetes: A Protocol for a Randomized Controlled Trial
ConclusionsThis will be the first randomized controlled trial to evaluate the safety and effectiveness of sodium-glucose co-transporter  2 inhibitors compared with lifestyle education for individuals with prediabetes.Trial RegistrationClinicalTrials.gov identifier NCT05914857 (registered 24 July 2023). (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 18, 2024 Category: Endocrinology Source Type: research

Insulin Use During Gestational and Pre-existing Diabetes in Pregnancy: A Systematic Review of Study Design
ConclusionThis SLR included a total of 108 clinical trials and observational studies with diverse populations and treatment arms. Outcomes varied across the studies, and a lack of consistent outcome measures to manage diabetes in pregnant women was observed. This elucidates a need for global consensus on study design and standardized clinical, maternal and fetal outcomes metrics. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 18, 2024 Category: Endocrinology Source Type: research

Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel
AbstractDespite the availability of various antihyperglycaemic therapies and comprehensive guidelines, glycaemic control in diabetes management has not improved significantly during the last decade in the real-world clinical setting. Treatment inertia arising from a complex interplay among patient-, clinician- and healthcare-system-related factors is the prime reason for this suboptimal glycaemic control. Also, the key factor leading to inadequate glycaemic levels remains limited communication between healthcare professionals (HCPs) and people with type 2 diabetes (PwT2D). Early insulin administration has several advantage...
Source: Diabetes Therapy - March 12, 2024 Category: Endocrinology Source Type: research

The Implication of Diabetes-Specialized Nurses in Aiming for the Better Treatment and Management of Patients with Diabetes Mellitus: A Brief Narrative Review
AbstractDiabetes mellitus (DM) is regarded as one of the most critical public health challenges of the 21st century. It has evolved into a burgeoning epidemic since the last century, and today ranks among the major causes of mortality worldwide. Diabetes specialist nurses (DSNs) are central to good patient care and outcomes including confident self-care management. Evidence shows that DSNs are cost-effective, improve clinical outcomes, and reduce length of stay in hospital. In this brief narrative review, we aim to describe the roles of DSNs and their contribution in the treatment and management of patients with DM. This n...
Source: Diabetes Therapy - March 12, 2024 Category: Endocrinology Source Type: research

Insulin Degludec in People with Type  2 Diabetes in China: A Non-interventional, Retrospective Chart Review Study (CN-TREAT)
ConclusionIn routine clinical practice in China, initiation or switching to degludec was associated with improvements in glycemic control in people with T2D, with no increased risk of hypoglycemia.Trial RegistrationClinialTrials.gov, NCT04227431. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 5, 2024 Category: Endocrinology Source Type: research

Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study
ConclusionsDulaglutide demonstrated better glycemic outcomes and lower all-cause costs per 1% HbA1c reduction among Hispanic/Latino adults compared with those initiating basal insulin. Our real-world findings in the Hispanic/Latino population were consistent with results obtained from the overall population and confirm the glycemic benefits of dulaglutide observed in clinical settings. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 1, 2024 Category: Endocrinology Source Type: research

Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study
ConclusionsBoth formulations of semaglutide provided clinically and statistically significant reductions in HbA1c and weight in real-world practice. Oral GLP-1 RA may offer a practical and effective option for the management of T2D. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 1, 2024 Category: Endocrinology Source Type: research

Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study
ConclusionsDulaglutide demonstrated better glycemic outcomes and lower all-cause costs per 1% HbA1c reduction among Hispanic/Latino adults compared with those initiating basal insulin. Our real-world findings in the Hispanic/Latino population were consistent with results obtained from the overall population and confirm the glycemic benefits of dulaglutide observed in clinical settings. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 1, 2024 Category: Endocrinology Source Type: research

Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study
ConclusionsBoth formulations of semaglutide provided clinically and statistically significant reductions in HbA1c and weight in real-world practice. Oral GLP-1 RA may offer a practical and effective option for the management of T2D. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 1, 2024 Category: Endocrinology Source Type: research

Impact of Glucagon-Like Peptide  1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study
ConclusionThese results demonstrate the potential for an alternate therapy, such as CRNT supported via telemedicine, to enable maintenance of weight loss and glycemia below therapeutic targets following discontinuation of GLP-1 therapy. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 29, 2024 Category: Endocrinology Source Type: research

Publisher Correction: Evaluation of Age-Related Changes in Teneligliptin Pharmacokinetics in Japanese and European Descent Subjects Using a Physiologically Based Pharmacokinetic Model
(Source: Diabetes Therapy)
Source: Diabetes Therapy - February 29, 2024 Category: Endocrinology Source Type: research

Impact of Glucagon-Like Peptide  1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study
ConclusionThese results demonstrate the potential for an alternate therapy, such as CRNT supported via telemedicine, to enable maintenance of weight loss and glycemia below therapeutic targets following discontinuation of GLP-1 therapy. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 29, 2024 Category: Endocrinology Source Type: research